Precision medicine is an approach to treatment and prevention that accounts for individual differences in genes, environment, and lifestyle. It represents a shift away from one-size-fits-all care toward decisions shaped by a patient's specific biology. Yet achieving health equity, in which every individual has the chance to attain their highest level of health regardless of background, remains a fundamental and unmet goal. Despite the promise of precision medicine, healthcare systems globally face significant challenges in providing equal access to these advances across all communities.
Disparities are visible across healthcare. Wait times in emergency care differ between genders and races. Maternal and infant health outcomes vary sharply across racial lines. Black individuals face higher instances of infant mortality and low birth weight, not due to natural causes but due to unequal levels of care.
The field of precision medicine reflects similar structural biases. Over 80% of genome data is derived from individuals of European descent, concentrating research focus on populations already well-represented in clinical databases and overlooking diseases prevalent in diverse communities.
Understanding these gaps matters for clinical development. Underrepresentation in genomic databases affects the validity and generalisability of genetically stratified research. Limited testing access constrains trial recruitment. These are not peripheral concerns—they shape how programs perform.
Key Takeaways
- Health Equity Gaps: Precision medicine currently reflects significant biases, with over 80% of genomic data derived from individuals of European descent.
- Access Barriers: High costs, limited insurance coverage, and the "digital divide" prevent underserved communities from accessing genomic testing and digital health tools.
- Stakeholder Roles: Healthcare providers, policymakers, and the pharma industry must collaborate to reform reimbursement policies and diversify clinical research.
- Actionable Strategies: Building inclusive genomic databases and implementing cultural competency training are essential steps toward equitable healthcare.
Characterizing disparities in precision medicine access and implementation
Precision medicine moves away from one-size-fits-all treatment by incorporating individual genetic, environmental, and lifestyle factors into clinical decisions. This approach works only when the underlying data, testing infrastructure, and care pathways are accessible to all populations. Today, they are not. Significant disparities exist in access to precision medicine technologies, particularly among underserved and minority populations. These gaps do not just reflect broader healthcare inequality. They actively limit the reach and effectiveness of precision approaches.
One of the primary disparities relates to the accessibility of genomic testing and personalized therapies. A study examining several genetic disorders with first-tier guidelines, including Familial Hypercholesterolemia (FH), Lynch syndrome, and hereditary breast and ovarian cancer, found that guideline implementation is lacking across the entire population. It is notably lower among racial and ethnic minority groups, women, residents of rural communities, the uninsured or underinsured, and those with lower education and income. A few examples illustrate the problem:
- Non-Hispanic black women have lower rates of BRCA testing compared to their non-Hispanic white counterparts, which is attributed to reduced discussions about testing with healthcare providers and limited referrals to genetic counselors among physicians serving minority populations. Consequently, Black women have lower rates of risk-reducing mastectomy and salpingo-oophorectomy.
- Among those with FH, individuals in racial and ethnic minority groups, those with lower incomes, and women are less likely to start treatment with PCSK9 inhibitors and more likely to be denied insurance coverage for these treatments.
The high cost of genomic testing and limited insurance coverage put these services out of reach for many, especially those from lower socioeconomic backgrounds. At the same time, diverse populations remain underrepresented in genomic databases. Because precision medicine depends on data that reflects individual variability in genes, environment, and lifestyle, gaps in representation directly reduce the accuracy and relevance of findings for underserved groups. This creates a compounding cycle: populations excluded from the data are also excluded from the benefits.
Another significant barrier is the digital divide. Precision medicine increasingly relies on digital health tools and electronic health records to gather patient data, monitor outcomes, and inform treatment decisions. Individuals with limited access to technology or broadband internet are effectively excluded from these workflows.
This divide does not only limit patient access. It also restricts the ability of healthcare providers to deliver personalized care to all segments of the population, particularly in rural or under-resourced settings where digital infrastructure remains uneven.
Expanding digital access must also account for applicable data protection requirements, including HIPAA in the United States and GDPR in Europe, to ensure that broader participation in genomic research does not come at the cost of patient privacy.
There is also a persistent lack of awareness and education about precision medicine among both patients and healthcare providers in underserved communities. Without adequate knowledge of what precision medicine involves and how it applies to treatment and prevention decisions, patients do not seek out or get offered these options. Healthcare providers serving these communities are often not equipped with up-to-date information on available precision medicine technologies or how to access them for their patients.
This gap has consequences beyond individual care. When patients are unaware of precision approaches, they are also less likely to participate in the clinical research that drives these therapies forward, further widening the gap between populations who benefit and those who do not.
Addressing these disparities requires coordinated investment across several areas: - Increasing the affordability and accessibility of genomic testing - Improving the representation of diverse populations in genomic research - Bridging the digital divide in healthcare delivery - Strengthening education about precision medicine for both patients and providers
Without progress across these dimensions, precision medicine will continue to deliver uneven value, benefiting well-served populations while leaving others behind.
Stakeholders responsible for addressing precision medicine disparities
Closing the access gap in precision medicine requires coordinated action across three groups: healthcare providers, policymakers, and the pharma/biotech industry. Each plays a distinct but interconnected role in shaping whether precision approaches reach all patients or only those already well-served by the system.
- Healthcare providers: Must navigate high costs and integrate genomic medicine into practice through revamped insurance benefits and enhanced medical education.
- Policymakers: Responsible for reforming reimbursement policies for genetic testing and ensuring services reach underserved communities.
- Pharma/biotech: Must combat structural biases by diversifying clinical trials, research projects, and leadership teams.
Strategies for improving equity in precision medicine
Several foundational strategies are already demonstrating how the access gap in precision medicine can be narrowed. These span data infrastructure, cross-institutional collaboration, community-level outreach, and workforce training. Each addresses a different structural barrier, and the most effective programs combine multiple approaches.
- Building diverse genomic databases: Creating inclusive datasets (e.g., Silent Genomes Project) to include First Nations, Inuit, and Métis populations.
- Expanding access through collaboratives: Utilizing initiatives like PROFYLE to offer nationwide molecular tumor profiling regardless of patient location.
- Launching targeted awareness campaigns: Partnering with community organizations to address specific risks, such as prostate cancer in Black men.
- Implementing cultural competency training: Training professionals to improve patient engagement and reduce disparities across diverse communities.
Conclusion
The disparities outlined here, from the underrepresentation of diverse populations in genomic databases to the digital divide limiting engagement with precision tools, are not peripheral concerns. They are structural constraints that shape which patients benefit from precision medicine and which do not.
Addressing these barriers requires coordinated action from healthcare providers, policymakers, and the pharma/biotech industry. Genomic testing, personalized therapies, and digital health infrastructure need to be accessible across populations, not concentrated among those already well-served by existing systems.
For sponsors and clinical teams developing precision therapies, this is also a research design question. Trials built on narrow or non-representative data produce findings with limited generalizability. Expanding access to precision medicine is not only an equity imperative. It is a prerequisite for generating the evidence these therapies require.
To learn more about the importance of diversity, equity, and inclusion in precision medicine research, download our whitepaper.